Uncategorized
Avedro resubmits NDA for riboflavin, corneal cross-linking system
Avedro announced the resubmission of its New Drug Application to the U.S. Food and Drug Administration for the riboflavin ophthalmic solution/KXL system.The company resubmitted its application in response to questions and requests included in the FDA’s complete response letter in March, according to the release.